ClinicalTrials.gg
CompletedNCT05885828Updated Sep 29, 2026

The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes

An interventional study of White bread and Whole wheat bread in Type 2 Diabetes, sponsored by Westlake University. Completed at 2 sites in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Westlake University · Not applicable, Interventional, and Other

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
438th of 769
144 · median 192
Started
2023
with 61 others
No phase
195 of 913
55 open now
Registered
581st of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 438th largest by enrollment of the 769 interventional ones that give a count, is one of 62 that started in 2023, is one of 195 with no phase, and was the 581st registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.

In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.

Read the detailed description

Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.

Study population: Patients with type 2 diabetes.

Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.

Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.

Dietary intervention:

The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • N-of-1
  • plant-based diet
  • precision nutrition
  • continuous glucose monitoring
  • type 2 diabetes
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes;
  • Living in Hangzhou for at least five years;
  • Have the willingness or ability to complete the intervention and sample collection

Exclusion criteria

Exclusion Criteria:

  • Mental and physical disability;
  • Already is a vegetarian;
  • Cancer and serious complications from type 2 diabetes, such as renal failure;
  • Using insulin for more than 5 years;
  • Unstable medical/medication status;
  • Current alcohol or drug abuse;
  • Taking antibiotics in the last three months
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Plant-based diet

    Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period.

    Other: White bread · Other: Whole wheat bread · Behavioral: Plant-based diet · Other: Follow-up visit every 1-2 years

  • Experimental
    Conventional diabetic diet

    Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period.

    Other: White bread · Other: Whole wheat bread · Other: Conventional diabetic diet · Other: Follow-up visit every 1-2 years

Interventions

  • OtherWhite bread

    After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

    Also known as: Breakfast A

  • OtherWhole wheat bread

    After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

    Also known as: Breakfast B

  • BehavioralPlant-based diet

    After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.

  • OtherConventional diabetic diet

    Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.

  • OtherFollow-up visit every 1-2 years

    Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

06

What researchers measure

Primary outcomes

  1. Continuous glucose monitoring-derived mean blood glucose

    Real-time glucose profiles will be recorded using continuous glucose monitoring. Average of all glucose measurements during the up to 14 days CGM wear will be calculated in mmol/L.

    Time frame: 2 weeks

  2. Continuous glucose monitoring-derived time-in-range

    Real-time glucose profiles will be recorded using continuous glucose monitoring. Percentage of glucose measurements that wear in the range of 3.9-10.0 mmol/L during the up to 14 days CGM will be calculated.

    Time frame: 2 weeks

  3. Continuous glucose monitoring-derived coefficient of variation

    Continuous glucose monitoring-derived time-in-range Real-time glucose profiles will be recorded using continuous glucose monitoring. Coefficient of variation was defined as standard deviation divided by mean glucose and multiplied by 100, during the up to 14 days wear.

    Time frame: two weeks

  4. Changes in gut microbiome profile

    Shotgun metagenomic sequencing will be performed in stool samples.

    Time frame: Day 1, 15 and 31

Secondary outcomes

  1. Changes in fasting blood glucose

    Fasting glucose will be examined in mmol/L.

    Time frame: Day 1, 15 and 31

  2. Changes in fasting blood C-peptide

    Fasting blood C-peptide will be examined in μg/L.

    Time frame: Day 1, 15 and 31

  3. Changes in fasting blood HbA1c

    Fasting blood HbA1c will be examined in %.

    Time frame: Day 1, 15 and 31

  4. Changes in lipid metabolism

    Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L.

    Time frame: Day 1, 15 and 31

07

Study locations

2 sites
  • Westlake University
    Hangzhou, Zhejiang 310030, China
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang 310058, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jan 2026, 29 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 29 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Dec 2025 → Jan 2026 and completion Dec 2033 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Jun 2, 2023
StartActual
Jul 17, 2023
Primary completionActual
Jan 4, 2026was Dec 2025
CompletionActual
Jan 4, 2026was Dec 2033
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Dec 31, 2025→Jan 4, 2026 (actual)
Sep 29, 2026
Study completion
Dec 1, 2033→Jan 4, 2026 (actual)
Sep 29, 2026
Enrollment
200 (estimated)→144 (actual)
Sep 29, 2026
Primary outcomes
1 time frame changed, 3 added, 1 removed
What changed in the outcomes
  • AddedContinuous glucose monitoring-derived mean blood glucoseTime frame: 2 weeks
  • AddedContinuous glucose monitoring-derived time-in-rangeTime frame: 2 weeks
  • AddedContinuous glucose monitoring-derived coefficient of variationTime frame: two weeks
  • RemovedBlood glucose profileTime frame: 2 weeks
  • Time frameChanges in gut microbiome profileDay 1 and Day 31 → Day 1, 15 and 31
Sep 29, 2026
Secondary outcomes
4 time frame changed, 4 removed
What changed in the outcomes
  • RemovedCarotid plaqueTime frame: At enrollment
  • RemovedCarotid intima-media thicknessTime frame: At enrollment
  • RemovedNumber of participants with chronic kidney diseaseTime frame: Up to 10 years
  • RemovedCognitive functionTime frame: Up to 10 years
  • Time frameChanges in fasting blood glucoseDay 1 and Day 31 → Day 1, 15 and 31
  • Time frameChanges in fasting blood C-peptideDay 1 and Day 31 → Day 1, 15 and 31
  • Time frameChanges in fasting blood HbA1cDay 1 and Day 31 → Day 1, 15 and 31
  • Time frameChanges in lipid metabolismDay 1 and Day 31 → Day 1, 15 and 31
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Jan 4, 2026 (now actual)
    Study completion Dec 1, 2033→Jan 4, 2026 (now actual)
    Enrollment 200 (estimated)→144 (actual)
    Primary outcomes 1 time frame changed, 3 added, 1 removed
    What changed in the outcomes
    • AddedContinuous glucose monitoring-derived mean blood glucoseTime frame: 2 weeks
    • AddedContinuous glucose monitoring-derived time-in-rangeTime frame: 2 weeks
    • AddedContinuous glucose monitoring-derived coefficient of variationTime frame: two weeks
    • RemovedBlood glucose profileTime frame: 2 weeks
    • Time frameChanges in gut microbiome profileDay 1 and Day 31 → Day 1, 15 and 31
    Secondary outcomes 4 time frame changed, 4 removed
    What changed in the outcomes
    • RemovedCarotid plaqueTime frame: At enrollment
    • RemovedCarotid intima-media thicknessTime frame: At enrollment
    • RemovedNumber of participants with chronic kidney diseaseTime frame: Up to 10 years
    • RemovedCognitive functionTime frame: Up to 10 years
    • Time frameChanges in fasting blood glucoseDay 1 and Day 31 → Day 1, 15 and 31
    • Time frameChanges in fasting blood C-peptideDay 1 and Day 31 → Day 1, 15 and 31
    • Time frameChanges in fasting blood HbA1cDay 1 and Day 31 → Day 1, 15 and 31
    • Time frameChanges in lipid metabolismDay 1 and Day 31 → Day 1, 15 and 31
    + 5 other changes: index terms, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05885828
Lead sponsor
Westlake University
Collaborators
The Third People's Hospital of Hangzhou
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jul 17, 2023
Primary completion
Jan 4, 2026
Completion
Jan 4, 2026
Last update
Sep 29, 2026

Study contacts

Ju-Sheng Zheng, PhD
principal investigator · Westlake University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion